Cidofovir Anhydrous

Summary

Cidofovir Anhydrous (CHEMBL152) is an approved small-molecule antiviral drug.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Clinical trials: 30
• Chemistry: 279.19 Da · C8H14N3O6P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL152
Name	Cidofovir Anhydrous
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	60613
ChEBI	CHEBI:3696
Molecular formula	C8H14N3O6P
Molecular weight	279.19
InChIKey	VWFCHDSQECPREK-LURJTMIESA-N

SMILES: C1=CN(C(=O)N=C1N)C[C@@H](CO)OCP(=O)(O)O

IUPAC name: [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid

ChEBI definition: Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.

Pharmacological roles (ChEBI): antiviral drug, antineoplastic agent, anti-HIV agent, photosensitizing agent.

Also known as: Anhydrous cidofovir, Bbs-1067, Bmy-28167, Cidofovir anhydrous, Hpmpc, Cidofovir

Parent form; salt/anhydrous children: CHEMBL5314375

Patent coverage: 7,087 distinct patent families (28,374 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 30.

Phase distribution

Phase	Trials
PHASE2	8
Not specified	7
PHASE1	6
PHASE3	4
PHASE4	3
PHASE2/PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00000894	PHASE4	COMPLETED	Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis
NCT00205374	PHASE4	COMPLETED	Use of Cidofovir for Recurrent Respiratory Papillomatosis
NCT01866397	PHASE4	COMPLETED	Pharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration
NCT07387367	PHASE3	RECRUITING	A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
NCT00000142	PHASE2/PHASE3	COMPLETED	Studies of the Ocular Complications of AIDS (SOCA)–HPMPC Peripheral CMV Retinitis Trial (HPCRT)
NCT00000143	PHASE3	COMPLETED	Studies of Ocular Complications of AIDS (SOCA)–Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
NCT02931539	PHASE3	COMPLETED	Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
NCT04055142	PHASE3	COMPLETED	Clinical Trial for Evaluating the Efficacy and Safety of Electrocoagulation vs Topic Sinecatechins vs Topic Cidofovir Within the Treatment to High-grade Anal Intraepithelial Neoplasia in HIV Homosexual Males
NCT01295645	PHASE2	ACTIVE_NOT_RECRUITING	Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis
NCT00002437	PHASE2	COMPLETED	The Safety and Effectiveness of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS
NCT00004794	PHASE2	COMPLETED	Phase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus Retinitis
NCT00019240	PHASE2	COMPLETED	Antiviral Therapy in Treating Patients With Kaposi’s Sarcoma With or Without HIV Infection
NCT00138424	PHASE1/PHASE2	TERMINATED	Cidofovir in Renal Transplant Recipients With BKVN
NCT00550589	PHASE2	COMPLETED	Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus
NCT02555800	PHASE2	UNKNOWN	Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis
NCT02567149	PHASE2	WITHDRAWN	Intralesional Cidofovir for the Treatment of Recalcitrant Warts in the Pediatric Immune-suppressed Population.
NCT02976987	PHASE2	COMPLETED	A Prolongation of a Clinical Study to Evaluate the Efficacy of an Aqueous Gel Containing 2% (w/w) of Cidofovir, Directly Applied on the Cervix Exhibiting High Grade Squamous Intraepithelial Lesions.
NCT00000881	PHASE1	WITHDRAWN	A Study of Cidofovir in HIV-Infected Children With Cytomegalovirus (CMV) Disease
NCT00001126	PHASE1	COMPLETED	Treatment With Cidofovir for Children With Laryngeal Papillomatosis (Warts in the Throat)
NCT00002116	PHASE1	COMPLETED	A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) in the Treatment of Refractory Mucocutaneous Herpes Simplex Disease in Patients With AIDS
NCT00002327	PHASE1	COMPLETED	The Safety and Effectiveness of Cidofovir in the Treatment of Venereal Warts in HIV-Infected Patients
NCT00811408	PHASE1	UNKNOWN	Cidofovir in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Who Are Receiving Chemotherapy and Radiation Therapy
NCT01816646	PHASE1	COMPLETED	Intravesical Cidofovir for Hemorrhagic Cystitis
NCT00000799	Not specified	COMPLETED	HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol
NCT00000945	Not specified	COMPLETED	A Study to Evaluate the Use of Cidofovir (an Experimental Drug) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in AIDS Patients
NCT00002142	Not specified	COMPLETED	An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS
NCT00002181	Not specified	COMPLETED	Cidofovir as a Treatment for Herpes Simplex in Patients With AIDS
NCT00002384	Not specified	UNKNOWN	A Study of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS
NCT00956176	Not specified	WITHDRAWN	Cidofovir Instillation in Hematopoietic Stem Cell Transplant (HSCT) Recipients With Hemorrhagic Cystitis
NCT01946009	Not specified	COMPLETED	A Prospective, With One Site, Open-label Not Controled Trial, for the Observation of Treatment With CIDOFOVIR 1%, 3 Nights Per Week, During 4 Weeks, of Anal Intraepithelial Neoplasia, High Level, in HIV+ Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 1 clinical and 1 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).